This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Roche Holding AG
Drug Names(s): CP-358774, erlotinib, OSI-774, R1415, RG1415, Ro50-8231, NSC 718781
Description: Tarceva is a small molecule that influences the biological activity of the epidermal growth factor receptor (EGFR). Other drugs that impact this target are Iressa, Erbitux, and ABX-EGF. AstraZeneca's Iressa, also a small molecule, is the first approved EGFR inhibitor. ImClone and Bristol Myers Squibb's Erbitux as well as Abgenix and Amgen's ABX-EGF are monoclonal antibodies.
Deal Structure: Revenue splits for this drug are BioMedTracker estimates.
Tarceva was originally developed by Pfizer.
In June 2000, Pfizer merged with Warner-Lambert. The resulting company retained the Pfizer name, but in order to meet Federal Trade Commission requirements for the merger, Pfizer granted a worldwide, royalty-free license for erlotinib to its developmental partner, OSI Pharmaceuticals.
Genentech (Roche) and OSI (Astellas)
Under the co-promotion arrangement, all U.S. sales of Tarceva and associated costs and expenses, except for a portion of OSI sales related costs, are recognized by Genentech. OSI records 50% share of the co-promotion pretax profit on a quarterly basis. Pretax co-promotion profit (loss) under the co-promotion arrangement is derived by calculating U.S. net sales of Tarceva to third-party customers and deducting costs of sales, distribution, selling and marketing expenses, and certain joint development expenses incurred by Genentech and OSI.
Partners: Astellas Pharma, Inc. Chugai Pharmaceutical Co., Ltd.
Additional information available to subscribers only: